Antidepression Medication Improves Quality of Life in Elderly Patients with Benign Prostatic Hyperplasia and Depression

Overview

Journal Int J Clin Exp Med

Specialty General Medicine

Date 2015 Jun 12

PMID 26064306

Authors

Lina Ma

Xiaoling Zhao

Huizhen Liu

Hong Zhu

Wei Yang

Yuying Qian

Jieyu Wang

Ming Feng

Yun Li

Affiliations

Soon will be listed here.

Abstract

We aim to explore the influence of an antidepression medication on symptom scores and quality of life in elderly patients with benign prostatic hyperplasia accompanied by depression. We conducted a randomized controlled clinical trial which included 94 elderly patients with benign prostatic hyperplasia accompanied by depression in Xuan Wu Hospital and Beijing Boai Hospital during August 2008 to May 2012. The study was designed to compare outcomes related to patient quality of life (QoL). The patients were randomly assigned to one of two groups, consisting of a control group (n = 47) and a therapy group (n = 47), and were followed up for 3 months. The pre-treatment and post-treatment changes among patients in the two groups were compared using their respective IPSS symptom scores, HAM-D scores, and scores on the Short Form 36 Health Survey. Following treatment, the patient IPSS symptom scores in the therapy group were significantly lower than those in the control group (10.74 ± 4.72 vs. 16.42 ± 8.09, respectively; t = 4.157, P < 0.05). Additionally, each measured dimension of QoL was significantly higher in the therapy group [total score (69.12 ± 3.92) vs. (61.30 ± 3.51), P < 0.05]. The results show antidepression medication can improve the symptoms and quality of life among elderly patients with benign prostatic hyperplasia accompanied by depression. Our findings suggest that an antidepression medication should be included when treating elderly patients with benign prostatic hyperplasia.

References

Fourcade R, Lacoin F, Roupret M, Slama A, Le Fur C, Michel E . Outcomes and general health-related quality of life among patients medically treated in general daily practice for lower urinary tract symptoms due to benign prostatic hyperplasia. World J Urol. 2011; 30(3):419-26. PMC: 3360843. DOI: 10.1007/s00345-011-0756-2. View

Irwin D, Kopp Z, Agatep B, Milsom I, Abrams P . Worldwide prevalence estimates of lower urinary tract symptoms, overactive bladder, urinary incontinence and bladder outlet obstruction. BJU Int. 2011; 108(7):1132-8. DOI: 10.1111/j.1464-410X.2010.09993.x. View

Wade A, Haring J . A review of the costs associated with depression and treatment noncompliance: the potential benefits of online support. Int Clin Psychopharmacol. 2010; 25(5):288-96. DOI: 10.1097/yic.0b013e328339fbcf. View

Sullivan S . Promoting health and productivity for depressed patients in the workplace. J Manag Care Pharm. 2005; 11(3 Suppl):S12-5. PMC: 10437877. DOI: 10.18553/jmcp.2005.11.3.S12. View

Humphreys D, Schlesinger L, Lopez M, Araya A . Interleukin-6 production and deregulation of the hypothalamic-pituitary-adrenal axis in patients with major depressive disorders. Endocrine. 2007; 30(3):371-6. DOI: 10.1007/s12020-006-0016-1. View

Johnson T, Abbasi A, Ehrlich S, Kleris R, Owen-Smith A, Raison C . IPSS quality of life question: a possible indicator of depression among patients with lower urinary tract symptoms. Can J Urol. 2012; 19(1):6100-4. View

Johnson T, Abbasi A, Ehrlich S, Kleris R, Chirumamilla S, Schoenberg E . Major depression drives severity of American Urological Association Symptom Index. Urology. 2010; 76(6):1317-20. DOI: 10.1016/j.urology.2010.01.069. View

Huang C, Chiu K, Chung S, Keller J, Huang C, Lin H . Increased risk of depressive disorder following the diagnosis of benign prostatic enlargement: one-year follow-up study. J Affect Disord. 2011; 135(1-3):395-9. DOI: 10.1016/j.jad.2011.07.001. View

Vallejo-Torres L, Castilla I, Gonzalez N, Hunter R, Serrano-Perez P, Perestelo-Perez L . Cost-effectiveness of electroconvulsive therapy compared to repetitive transcranial magnetic stimulation for treatment-resistant severe depression: a decision model. Psychol Med. 2014; 45(7):1459-70. PMC: 4413854. DOI: 10.1017/S0033291714002554. View

10.

Ustun T, Ayuso-Mateos J, Chatterji S, Mathers C, Murray C . Global burden of depressive disorders in the year 2000. Br J Psychiatry. 2004; 184:386-92. DOI: 10.1192/bjp.184.5.386. View

11.

Briesacher B, Gurwitz J, Soumerai S . Patients at-risk for cost-related medication nonadherence: a review of the literature. J Gen Intern Med. 2007; 22(6):864-71. PMC: 2219866. DOI: 10.1007/s11606-007-0180-x. View

12.

Coyne K, Wein A, Tubaro A, Sexton C, Thompson C, Kopp Z . The burden of lower urinary tract symptoms: evaluating the effect of LUTS on health-related quality of life, anxiety and depression: EpiLUTS. BJU Int. 2009; 103 Suppl 3:4-11. DOI: 10.1111/j.1464-410X.2009.08371.x. View

13.

Scuteri A, Spazzafumo L, Cipriani L, Gianni W, Corsonello A, Cravello L . Depression, hypertension, and comorbidity: disentangling their specific effect on disability and cognitive impairment in older subjects. Arch Gerontol Geriatr. 2010; 52(3):253-7. DOI: 10.1016/j.archger.2010.04.002. View

14.

Greenberg P, Kessler R, Birnbaum H, Leong S, Lowe S, Berglund P . The economic burden of depression in the United States: how did it change between 1990 and 2000?. J Clin Psychiatry. 2004; 64(12):1465-75. DOI: 10.4088/jcp.v64n1211. View

15.

Oelke M, Giuliano F, Mirone V, Xu L, Cox D, Viktrup L . Monotherapy with tadalafil or tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo-controlled clinical trial. Eur Urol. 2012; 61(5):917-25. DOI: 10.1016/j.eururo.2012.01.013. View

16.

Wang P, Simon G, Avorn J, Azocar F, Ludman E, McCulloch J . Telephone screening, outreach, and care management for depressed workers and impact on clinical and work productivity outcomes: a randomized controlled trial. JAMA. 2007; 298(12):1401-11. PMC: 2859667. DOI: 10.1001/jama.298.12.1401. View

17.

Krousel-Wood M, Frohlich E . Hypertension and depression: coexisting barriers to medication adherence. J Clin Hypertens (Greenwich). 2010; 12(7):481-6. PMC: 3050602. DOI: 10.1111/j.1751-7176.2010.00302.x. View

18.

Montorsi F, Henkel T, Geboers A, Mirone V, Arrosagaray P, Morrill B . Effect of dutasteride, tamsulosin and the combination on patient-reported quality of life and treatment satisfaction in men with moderate-to-severe benign prostatic hyperplasia: 4-year data from the CombAT study. Int J Clin Pract. 2010; 64(8):1042-51. DOI: 10.1111/j.1742-1241.2010.02428.x. View

19.

Kim J, Moon V . [Factors influencing health-related quality of life in patients with benign prostatic hyperplasia]. J Korean Acad Nurs. 2010; 40(2):287-97. DOI: 10.4040/jkan.2010.40.2.287. View

20.

Perchon L, Pintarelli V, Bezerra E, Thiel M, Dambros M . Quality of life in elderly men with aging symptoms and lower urinary tract symptoms (LUTS). Neurourol Urodyn. 2011; 30(4):515-9. DOI: 10.1002/nau.21008. View